Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190749 · ClinicalTrials.gov registry record · Phase 4
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT00190749: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00190749 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00190749, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
Primary Outcome
Normalized insulin sensitivity index (Mffm/I) was defined as the ratio of whole body glucose disposal rate normalized to fat-free mass (Mffm) divided by the plasma insulin concentration (I) during steady-state conditions of the clamp procedure. Units:\[(mg glucose)\*min\*mL\] / \[(kg fat free body mass)\*(micro IU insulin)\]
Interventions
- DRUG risperidone
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
What the finished NCT00190749 record still lists
NCT00190749 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00190749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00190749 about?
NCT00190749 is a clinical study titled "Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder". This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
What is the current status of trial NCT00190749?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2003-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00190749?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00190749?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00190749's enrollment target sits among peer trials
130 622nd of 2000 higher than 1,370 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia